These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 28040729)
21. Genetic and epigenetic contributors to FSHD. Daxinger L; Tapscott SJ; van der Maarel SM Curr Opin Genet Dev; 2015 Aug; 33():56-61. PubMed ID: 26356006 [TBL] [Abstract][Full Text] [Related]
22. PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level. Banerji CRS; Zammit PS Hum Mol Genet; 2019 Jul; 28(13):2224-2236. PubMed ID: 31067297 [TBL] [Abstract][Full Text] [Related]
23. A proteomics study identifying interactors of the FSHD2 gene product SMCHD1 reveals RUVBL1-dependent DUX4 repression. Goossens R; Tihaya MS; van den Heuvel A; Tabot-Ndip K; Willemsen IM; Tapscott SJ; González-Prieto R; Chang JG; Vertegaal ACO; Balog J; van der Maarel SM Sci Rep; 2021 Dec; 11(1):23642. PubMed ID: 34880314 [TBL] [Abstract][Full Text] [Related]
24. Cis D4Z4 repeat duplications associated with facioscapulohumeral muscular dystrophy type 2. Lemmers RJLF; van der Vliet PJ; Vreijling JP; Henderson D; van der Stoep N; Voermans N; van Engelen B; Baas F; Sacconi S; Tawil R; van der Maarel SM Hum Mol Genet; 2018 Oct; 27(20):3488-3497. PubMed ID: 30281091 [TBL] [Abstract][Full Text] [Related]
25. Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD). Zeng W; de Greef JC; Chen YY; Chien R; Kong X; Gregson HC; Winokur ST; Pyle A; Robertson KD; Schmiesing JA; Kimonis VE; Balog J; Frants RR; Ball AR; Lock LF; Donovan PJ; van der Maarel SM; Yokomori K PLoS Genet; 2009 Jul; 5(7):e1000559. PubMed ID: 19593370 [TBL] [Abstract][Full Text] [Related]
26. In junk we trust: repetitive DNA, epigenetics and facioscapulohumeral muscular dystrophy. Neguembor MV; Gabellini D Epigenomics; 2010 Apr; 2(2):271-87. PubMed ID: 22121874 [TBL] [Abstract][Full Text] [Related]
27. WDR5 is required for DUX4 expression and its pathological effects in FSHD muscular dystrophy. Mocciaro E; Giambruno R; Micheloni S; Cernilogar FM; Andolfo A; Consonni C; Pannese M; Ferri G; Runfola V; Schotta G; Gabellini D Nucleic Acids Res; 2023 Jun; 51(10):5144-5161. PubMed ID: 37021550 [TBL] [Abstract][Full Text] [Related]
28. Dnmt3b regulates DUX4 expression in a tissue-dependent manner in transgenic D4Z4 mice. Bouwman LF; den Hamer B; Verveer EP; Lerink LJS; Krom YD; van der Maarel SM; de Greef JC Skelet Muscle; 2020 Oct; 10(1):27. PubMed ID: 33004076 [TBL] [Abstract][Full Text] [Related]
29. Identification of Epigenetic Regulators of DUX4-fl for Targeted Therapy of Facioscapulohumeral Muscular Dystrophy. Himeda CL; Jones TI; Virbasius CM; Zhu LJ; Green MR; Jones PL Mol Ther; 2018 Jul; 26(7):1797-1807. PubMed ID: 29759937 [TBL] [Abstract][Full Text] [Related]
30. Smchd1 haploinsufficiency exacerbates the phenotype of a transgenic FSHD1 mouse model. de Greef JC; Krom YD; den Hamer B; Snider L; Hiramuki Y; van den Akker RFP; Breslin K; Pakusch M; Salvatori DCF; Slütter B; Tawil R; Blewitt ME; Tapscott SJ; van der Maarel SM Hum Mol Genet; 2018 Feb; 27(4):716-731. PubMed ID: 29281018 [TBL] [Abstract][Full Text] [Related]
31. The Genetics and Epigenetics of Facioscapulohumeral Muscular Dystrophy. Himeda CL; Jones PL Annu Rev Genomics Hum Genet; 2019 Aug; 20():265-291. PubMed ID: 31018108 [TBL] [Abstract][Full Text] [Related]
32. Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis. Jones TI; Chen JC; Rahimov F; Homma S; Arashiro P; Beermann ML; King OD; Miller JB; Kunkel LM; Emerson CP; Wagner KR; Jones PL Hum Mol Genet; 2012 Oct; 21(20):4419-30. PubMed ID: 22798623 [TBL] [Abstract][Full Text] [Related]
34. Large family cohorts of lymphoblastoid cells provide a new cellular model for investigating facioscapulohumeral muscular dystrophy. Jones TI; Himeda CL; Perez DP; Jones PL Neuromuscul Disord; 2017 Mar; 27(3):221-238. PubMed ID: 28161093 [TBL] [Abstract][Full Text] [Related]
35. Control of DUX4 Expression in Facioscapulohumeral Muscular Dystrophy and Cancer. Karpukhina A; Tiukacheva E; Dib C; Vassetzky YS Trends Mol Med; 2021 Jun; 27(6):588-601. PubMed ID: 33863674 [TBL] [Abstract][Full Text] [Related]
36. Dysregulation of 4q35- and muscle-specific genes in fetuses with a short D4Z4 array linked to facio-scapulo-humeral dystrophy. Broucqsault N; Morere J; Gaillard MC; Dumonceaux J; Torrents J; Salort-Campana E; Maues De Paula A; Bartoli M; Fernandez C; Chesnais AL; Ferreboeuf M; Sarda L; Dufour H; Desnuelle C; Attarian S; Levy N; Nguyen K; Magdinier F; Roche S Hum Mol Genet; 2013 Oct; 22(20):4206-14. PubMed ID: 23777630 [TBL] [Abstract][Full Text] [Related]
37. Asymmetric bidirectional transcription from the FSHD-causing D4Z4 array modulates DUX4 production. Block GJ; Petek LM; Narayanan D; Amell AM; Moore JM; Rabaia NA; Tyler A; van der Maarel SM; Tawil R; Filippova GN; Miller DG PLoS One; 2012; 7(4):e35532. PubMed ID: 22536400 [TBL] [Abstract][Full Text] [Related]
38. Methylation of the FSHD syndrome-linked subtelomeric repeat in normal and FSHD cell cultures and tissues. Tsien F; Sun B; Hopkins NE; Vedanarayanan V; Figlewicz D; Winokur S; Ehrlich M Mol Genet Metab; 2001 Nov; 74(3):322-31. PubMed ID: 11708861 [TBL] [Abstract][Full Text] [Related]
39. DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy? Tassin A; Laoudj-Chenivesse D; Vanderplanck C; Barro M; Charron S; Ansseau E; Chen YW; Mercier J; Coppée F; Belayew A J Cell Mol Med; 2013 Jan; 17(1):76-89. PubMed ID: 23206257 [TBL] [Abstract][Full Text] [Related]